DALLAS-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。